HTL0014242
Neurological Disorders
PreclinicalActive
Key Facts
About Nxera Pharma
Nxera Pharma is a Tokyo-listed biopharma company that rebranded from Sosei Group in 2023 to reflect its evolution into a fully integrated R&D and commercial entity. Its core strategy is built on a GPCR-focused technology platform, strategic partnerships with major pharmaceutical companies, and a pipeline targeting high-need areas in CNS and immunology. The company aims to become a leading, innovation-driven biopharma player in the Asia-Pacific region and globally.
View full company profileTherapeutic Areas
Other Neurological Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| CNS Programs | Fosun Pharma | Various Phases |
| CNS Portfolio | Aurobindo Pharma | Commercial |
| CNS-directed programs | Beam Therapeutics | Discovery/Preclinical |
| ExacTcell Platform | Tevogen Bio | Pre-clinical |